%0 Journal Article
%T Therapeutic effects of the novel Leucyl-tRNA synthetase inhibitor BC-LI-0186 in non-small cell lung cancer
%A Arum Kim
%A Chulho Lee
%A Eun Young Kim
%A Gyoonhee Han
%A Hee Chan Yoo
%A Jin Gu Lee
%A Jung Min Han
%A Jung Mo Lee
%A Kibum Kim
%A Minji Lee
%A Yoon Soo Chang
%J Archive of "Therapeutic Advances in Medical Oncology".
%D 2019
%R 10.1177/1758835919846798
%X Leucyl-tRNA synthetase (LRS) is an aminoacyl-tRNA synthetase catalyzing ligation of leucine to its cognate tRNA and is involved in the activation of mTORC1 by sensing cytoplasmic leucine. In this study, the usefulness of LRS as a therapeutic target of non-small cell lung cancer (NSCLC) and the anticancer effect of the LRS inhibitor, BC-LI-0186, was evaluated
%K aminoacyl-tRNA synthetase (ARS)
%K BC-LI-0186
%K leucyl-tRNA synthetase (LRS)
%K mTORC1
%K non-small cell lung cancer (NSCLC)
%U https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6535710/